Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
RCT (n=747) reports rimegepant, a novel calcitonin gene-related peptide receptor antagonist, was superior to placebo for change in mean number of migraine days per month during weeks 9–12 (−4.3 days vs. −3.5, respectively; mean difference −0.8, 95% CI −1.46 to −0.20; p=0.0099).
Source:
The Lancet
SPS commentary:
Authors’ of a related commentary highlight benefit of oral formulation taken every other day; and that tolerability was similar to that of placebo, and no unexpected or serious safety issues were noted in the study.